A comparison of tacrolimus and cyclosporine in liver transplantation: Effects on renal function and cardiovascular risk status

Michael R. Lucey, Manal F. Abdelmalek, Rosemarie Gagliardi, Darla Granger, Curtis Holt, Igal Kam, Goran Klintmalm, Alan Norman Langnas, Kirti Shetty, Andreas Tzakis, E. Steve Woodle

Research output: Contribution to journalReview article

69 Citations (Scopus)

Abstract

A retrospective chart review of 1065 consecutive liver allograft recipients in 11 centers from January 1997 to September 1998 was performed. Patients were followed for 3 years or until graft loss. Patients received either tacrolimus (n = 594), cyclosporine (n = 450) or no calcineurin inhibitor (n = 21). Model for end-stage liver disease (MELD) scores at time of transplant were similar between the two groups. During follow-up, more patients switched from cyclosporine to tacrolimus (26.7%) than from tacrolimus to cyclosporine (12.8%; p < 0.0001). Patient and graft survival were equivalent. Corticosteroid use was more common in cyclosporine-treated patients (p < 0.00001). Patients receiving tacrolimus experienced lower serum creatinine levels at months 3 through 36 (p < 0.0001). Systolic blood pressure was lower in patients receiving tacrolimus (p < 0.001) despite a reduced requirement for anti-hypertensive agents (p < 0.0001). In addition, tacrolimus was associated with lower total cholesterol and triglyceride levels for months 3 through 24 and 3 through 12, respectively (p < 0.01), despite a reduced requirement for anti-hyperlipidemic agents. The incidence of new-onset diabetes mellitus was similar in both groups. While both calcineurin inhibitors were associated with excellent patient and graft survival, renal function, blood pressure and serum lipid levels were significantly better with tacrolimus treatment.

Original languageEnglish (US)
Pages (from-to)1111-1119
Number of pages9
JournalAmerican Journal of Transplantation
Volume5
Issue number5
DOIs
StatePublished - May 1 2005

Fingerprint

Tacrolimus
Liver Transplantation
Cyclosporine
Kidney
Graft Survival
Blood Pressure
Transplants
End Stage Liver Disease
Serum
Antihypertensive Agents
Allografts
Creatinine
Diabetes Mellitus
Adrenal Cortex Hormones
Triglycerides
Cholesterol
Lipids
Liver
Incidence

Keywords

  • Cardiovascular risk
  • Cyclosporine
  • Liver transplantation
  • Renal function
  • Tacrolimus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

A comparison of tacrolimus and cyclosporine in liver transplantation : Effects on renal function and cardiovascular risk status. / Lucey, Michael R.; Abdelmalek, Manal F.; Gagliardi, Rosemarie; Granger, Darla; Holt, Curtis; Kam, Igal; Klintmalm, Goran; Langnas, Alan Norman; Shetty, Kirti; Tzakis, Andreas; Woodle, E. Steve.

In: American Journal of Transplantation, Vol. 5, No. 5, 01.05.2005, p. 1111-1119.

Research output: Contribution to journalReview article

Lucey, MR, Abdelmalek, MF, Gagliardi, R, Granger, D, Holt, C, Kam, I, Klintmalm, G, Langnas, AN, Shetty, K, Tzakis, A & Woodle, ES 2005, 'A comparison of tacrolimus and cyclosporine in liver transplantation: Effects on renal function and cardiovascular risk status', American Journal of Transplantation, vol. 5, no. 5, pp. 1111-1119. https://doi.org/10.1111/j.1600-6143.2005.00808.x
Lucey, Michael R. ; Abdelmalek, Manal F. ; Gagliardi, Rosemarie ; Granger, Darla ; Holt, Curtis ; Kam, Igal ; Klintmalm, Goran ; Langnas, Alan Norman ; Shetty, Kirti ; Tzakis, Andreas ; Woodle, E. Steve. / A comparison of tacrolimus and cyclosporine in liver transplantation : Effects on renal function and cardiovascular risk status. In: American Journal of Transplantation. 2005 ; Vol. 5, No. 5. pp. 1111-1119.
@article{57f70457b17347e4b5ed91c88607d1ea,
title = "A comparison of tacrolimus and cyclosporine in liver transplantation: Effects on renal function and cardiovascular risk status",
abstract = "A retrospective chart review of 1065 consecutive liver allograft recipients in 11 centers from January 1997 to September 1998 was performed. Patients were followed for 3 years or until graft loss. Patients received either tacrolimus (n = 594), cyclosporine (n = 450) or no calcineurin inhibitor (n = 21). Model for end-stage liver disease (MELD) scores at time of transplant were similar between the two groups. During follow-up, more patients switched from cyclosporine to tacrolimus (26.7{\%}) than from tacrolimus to cyclosporine (12.8{\%}; p < 0.0001). Patient and graft survival were equivalent. Corticosteroid use was more common in cyclosporine-treated patients (p < 0.00001). Patients receiving tacrolimus experienced lower serum creatinine levels at months 3 through 36 (p < 0.0001). Systolic blood pressure was lower in patients receiving tacrolimus (p < 0.001) despite a reduced requirement for anti-hypertensive agents (p < 0.0001). In addition, tacrolimus was associated with lower total cholesterol and triglyceride levels for months 3 through 24 and 3 through 12, respectively (p < 0.01), despite a reduced requirement for anti-hyperlipidemic agents. The incidence of new-onset diabetes mellitus was similar in both groups. While both calcineurin inhibitors were associated with excellent patient and graft survival, renal function, blood pressure and serum lipid levels were significantly better with tacrolimus treatment.",
keywords = "Cardiovascular risk, Cyclosporine, Liver transplantation, Renal function, Tacrolimus",
author = "Lucey, {Michael R.} and Abdelmalek, {Manal F.} and Rosemarie Gagliardi and Darla Granger and Curtis Holt and Igal Kam and Goran Klintmalm and Langnas, {Alan Norman} and Kirti Shetty and Andreas Tzakis and Woodle, {E. Steve}",
year = "2005",
month = "5",
day = "1",
doi = "10.1111/j.1600-6143.2005.00808.x",
language = "English (US)",
volume = "5",
pages = "1111--1119",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - A comparison of tacrolimus and cyclosporine in liver transplantation

T2 - Effects on renal function and cardiovascular risk status

AU - Lucey, Michael R.

AU - Abdelmalek, Manal F.

AU - Gagliardi, Rosemarie

AU - Granger, Darla

AU - Holt, Curtis

AU - Kam, Igal

AU - Klintmalm, Goran

AU - Langnas, Alan Norman

AU - Shetty, Kirti

AU - Tzakis, Andreas

AU - Woodle, E. Steve

PY - 2005/5/1

Y1 - 2005/5/1

N2 - A retrospective chart review of 1065 consecutive liver allograft recipients in 11 centers from January 1997 to September 1998 was performed. Patients were followed for 3 years or until graft loss. Patients received either tacrolimus (n = 594), cyclosporine (n = 450) or no calcineurin inhibitor (n = 21). Model for end-stage liver disease (MELD) scores at time of transplant were similar between the two groups. During follow-up, more patients switched from cyclosporine to tacrolimus (26.7%) than from tacrolimus to cyclosporine (12.8%; p < 0.0001). Patient and graft survival were equivalent. Corticosteroid use was more common in cyclosporine-treated patients (p < 0.00001). Patients receiving tacrolimus experienced lower serum creatinine levels at months 3 through 36 (p < 0.0001). Systolic blood pressure was lower in patients receiving tacrolimus (p < 0.001) despite a reduced requirement for anti-hypertensive agents (p < 0.0001). In addition, tacrolimus was associated with lower total cholesterol and triglyceride levels for months 3 through 24 and 3 through 12, respectively (p < 0.01), despite a reduced requirement for anti-hyperlipidemic agents. The incidence of new-onset diabetes mellitus was similar in both groups. While both calcineurin inhibitors were associated with excellent patient and graft survival, renal function, blood pressure and serum lipid levels were significantly better with tacrolimus treatment.

AB - A retrospective chart review of 1065 consecutive liver allograft recipients in 11 centers from January 1997 to September 1998 was performed. Patients were followed for 3 years or until graft loss. Patients received either tacrolimus (n = 594), cyclosporine (n = 450) or no calcineurin inhibitor (n = 21). Model for end-stage liver disease (MELD) scores at time of transplant were similar between the two groups. During follow-up, more patients switched from cyclosporine to tacrolimus (26.7%) than from tacrolimus to cyclosporine (12.8%; p < 0.0001). Patient and graft survival were equivalent. Corticosteroid use was more common in cyclosporine-treated patients (p < 0.00001). Patients receiving tacrolimus experienced lower serum creatinine levels at months 3 through 36 (p < 0.0001). Systolic blood pressure was lower in patients receiving tacrolimus (p < 0.001) despite a reduced requirement for anti-hypertensive agents (p < 0.0001). In addition, tacrolimus was associated with lower total cholesterol and triglyceride levels for months 3 through 24 and 3 through 12, respectively (p < 0.01), despite a reduced requirement for anti-hyperlipidemic agents. The incidence of new-onset diabetes mellitus was similar in both groups. While both calcineurin inhibitors were associated with excellent patient and graft survival, renal function, blood pressure and serum lipid levels were significantly better with tacrolimus treatment.

KW - Cardiovascular risk

KW - Cyclosporine

KW - Liver transplantation

KW - Renal function

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=20244362068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244362068&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2005.00808.x

DO - 10.1111/j.1600-6143.2005.00808.x

M3 - Review article

C2 - 15816894

AN - SCOPUS:20244362068

VL - 5

SP - 1111

EP - 1119

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 5

ER -